Systemic Sclerosis and Atherosclerosis: Potential Cellular Biomarkers and Mechanisms
Frontiers in Bioscience-Scholar · 26.12.2023 · 15 (4)
DOI: 10.31083/j.fbs1504016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Scholar, online erschienen am 26.12.2023. Verfasst von Elena V Gerasimova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systemic Rheumatic Diseases, V.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russian Federation. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Atherosclerosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Systemic sclerosis (SSc) is a rare systemic autoimmune disease of unknown etiology, which is characterized by endothelial dysfunction, pathologic vasculopathy, and increased tissue fibrosis. Traditionally, SSc has been regarded as a prototypical fibrotic disease in the family of systemic autoimmune diseases. Traditionally, emphasis has been placed on the three components of the pathogenesis of SSc: vascular, immune, and mesenchymal. Microvascular lesions, including endothelial dysfunction and smooth muscle cell migration into the intima of vessels in SSc, resemble the atherosclerotic process. Although microvascular disease is a hallmark of SSc, understanding the role of atherosclerotic vascular lesions in patients with SSc remains limited. It is still unknown whether the increased cardiovascular risk in SSc is related to specific cardiac complications (such as myocardial fibrosis) or the accelerated development of atherosclerosis. Different immune cell types appear to be involved in the immunopathogenesis of SSc via the activation of other immune cells, fibrosis, or vascular damage. Macrophages, B cells, T cells, dendritic cells, neutrophils, and endothelial cells have been reported to play the most important role in the pathogenesis of SSc and atherosclerosis. In our article, we reviewed the most significant and recent studies on the pathogenetic links between the development of SSc and the atherosclerotic process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systemic Rheumatic Diseases, V.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russian Federation.
- Department of Organization and Economics of Pharmacy, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Fed…
Förderung
- Russian Science Foundation
Zitieren
APA
Gerasimova, E. V., Shayakhmetova, R. U., Gerasimova, D. A., Popkova, T. V., & Ananyeva, L. P. (2023). Systemic Sclerosis and Atherosclerosis: Potential Cellular Biomarkers and Mechanisms. Frontiers in Bioscience-Scholar, 15(4). https://doi.org/10.31083/j.fbs1504016
Vancouver
Gerasimova EV, Shayakhmetova RU, Gerasimova DA, Popkova TV, Ananyeva LP. Systemic Sclerosis and Atherosclerosis: Potential Cellular Biomarkers and Mechanisms. Frontiers in Bioscience-Scholar. 2023;15(4). doi:10.31083/j.fbs1504016
BibTeX
@article{Gerasimova2023,
author = {Gerasimova, Elena V and Shayakhmetova, Rushana U and Gerasimova, Daria A and Popkova, Tatiana V and Ananyeva, Lidia P},
title = {Systemic Sclerosis and Atherosclerosis: Potential Cellular Biomarkers and Mechanisms},
journal = {Frontiers in Bioscience-Scholar},
year = {2023},
volume = {15},
number = {4},
doi = {10.31083/j.fbs1504016}
}
EUVIMED